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Extracellular signal-regulated kinase (ERK) 1/2, a well known regulator of gene expression, is likely to contribute to signaling events
underlying enduring neural adaptations. Phosphorylated (phospho)-ERK was examined immunohistochemically after both single and
repeated (i.e., sensitizing) doses of the partial D1-dopamine (DA) receptor agonist SKF-38393 (2,3,4,5-tetrahydro-7,8-dihydroxy-1-
phenyl-1H-3-benazepine HCl) to adult rats lesioned as neonates (neonate lesioned) with 6-hydroxydopamine. Remarkably, prolonged
phospho-ERK accumulated primarily in layers II–III of medial prefrontal cortex (MPC), where it declined gradually yet remained
significantly elevated for at least 36 d after repeated doses of SKF-38393. Sustained (7 d) phospho-ERK was observed for shorter periods
in various other cortical regions but was not detectable in striatum or nucleus accumbens. At 36 d, an additional injection of SKF-38393
to sensitized rats restored phospho-ERK to maximal levels only in MPC when examined 7 d later. Phosphorylated cAMP response
element-binding protein (CREB), examined 7 d after the sensitizing regimen, was observed exclusively in MPC, where it was abundant
throughout all layers. Systemic injections of SL327 (-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)benzeneaceto-
nitrile), an inhibitor of the upstream ERK activator mitogen ERK kinase, attenuated both ERK and CREB phosphorylation in layers II–III
of MPC. Pretreatment with the D1 antagonist SCH-23390 ((R)-()-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-1H-3-benzazepine-
7-OL maleate) inhibited the prolonged increase in MPC phospho-ERK, whereas the 5-HT2 receptor antagonist ketanserin (3-[2-[4-(4-
fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione tartrate) was ineffective. Competitive and noncompetitive NMDA
receptor antagonists also blocked sustained ERK phosphorylation. Collectively, the present results demonstrate coupling of D1 and
NMDA receptor function reflected in sustained activation of the ERK signaling pathway in MPC of SKF-38393-sensitized neonate-
lesioned rats. Ultimately, long-lasting phosphorylation of ERK and CREB in MPC may play a pivotal role in any permanent adaptive
change(s) in these animals.
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Introduction
Administration of the neurotoxicant 6-hydroxydopamine (6-
OHDA), with desmethylimipramine pretreatment, results in the
selective destruction of dopamine-containing neurons (Smith et
al., 1973). Rats bilaterally lesioned with 6-OHDA as neonates
have increased susceptibility for aggression, hyperexcitability,
and self-injurious behavior in response to dopamine (DA) recep-
tor agonists (Breese et al., 1984). These behaviors are similar to
those observed clinically with Lesch–Nyhan syndrome (LNS), a
developmental disorder characterized by reduced brain DA, cho-
reoathetoid movements, and compulsive self-injurious behavior
(Lesch and Nyhan, 1964). The susceptibility for self-injurious
behavior observed in neonate-lesioned rats is not present in rats
lesioned with 6-OHDA as adults, the latter of which mimic Par-
kinson’s disease (Breese et al., 1984; Marsden, 1984). Thus, the
neonatal rat brain must retain sufficient plasticity to allow for the
development of compensatory mechanisms that attenuate, to
some degree, the debilitating effects of DA depletion.
Repeated dosing with the D1-dopamine receptor agonist SKF-
38393 (2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-bena-
zepine HCl) to neonate-lesioned rats results in long-lasting be-
havioral sensitization, which is seen as an agonist-induced in-
crease in locomotor activity for at least 6 months after the sensi-
tization (Breese et al., 1984; Criswell et al., 1989). Treatment with
D1 receptor antagonists blocks the increasing motor responsive-
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ness (Breese et al., 1985a,b; Criswell et al., 1989, 1990), a finding
that demonstrates a requirement for D1 receptor activation in
SKF-38393-mediated sensitization of these animals. Studies have
shown that the sensitization is not dependent on contextual cues
associated with SKF-38393 administration (Criswell et al., 1989),
nor is it related to changes in density or binding affinity of D1
receptors in striatum (Breese et al., 1987).
Central to the notion that SKF-38393-mediated sensitization
of neonate-lesioned rats relates to behavioral and neural plastic-
ity is the discovery that pretreatment with the noncompetitive
NMDA receptor antagonist MK-801 (()-5-methyl-10,11-
dihydroxy-5H-dibenzo(a,d)cyclohepten-5,10-imine) abolishes
this sensitization (Criswell et al., 1990). It is well established that
NMDA receptor activation is critical for development of psy-
chomotor stimulant-induced behavioral sensitization (Karler et
al., 1989; Stewart and Druhan, 1993; Wolf and Jeziorski, 1993)
and that NMDA receptor antagonists interfere with long-term
potentiation, a model of learning and memory formation (Lynch
et al., 1983; Davis et al., 1992; for review, see Riedel et al., 2003).
These findings have established a critical role for NMDA
receptor-dependent mechanisms that can lead to persistent cel-
lular and behavioral adaptive changes. Thus, the finding that
MK-801 antagonizes SKF-38393-mediated sensitization in
neonate-lesioned rats supports consideration of this model as a
type of “neuronal learning” (Criswell et al., 1989).
The discovery of specific neurobiological substrates of adaptive
change(s) that accompany the enduring hyper-responsiveness of
neonate-lesioned rats to repeated D1 receptor stimulation might
provide insight into developmental and other disorders involving
permanent DA-mediated sensitization, such as schizophrenia
and psychostimulant abuse. A likely candidate, extracellular
signal-regulated kinase (ERK) 1/2, is a cell-signaling molecule
thought to be critical for various forms of neuroplasticity. Stim-
ulation of D1 and NMDA receptors can recruit several second
messenger systems to activate ERK (Xia et al., 1996; Sweatt,
2001). In this respect, Gerfen et al. (2002) demonstrated en-
hanced striatal ERK phosphorylation after acute SKF-38393 ad-
ministration in unilateral adult 6-OHDA-lesioned rats. Further-
more, immediate-early gene transcription in DA-depleted
striatum was ERK dependent, a finding that suggests ERK path-
way involvement in adaptive changes occurring in these animals
(Gerfen et al., 2002). Neuronal ERK phosphorylation has been
linked to a number of other cellular signaling processes (for re-
view, see Adams and Sweatt, 2002). Among these, activation of
the transcription factor cAMP response element-binding protein
(CREB) has emerged as a major regulatory mechanism for
activity-dependent neuroplasticity (Lonze and Ginty, 2002).
The aim of the present study was to investigate whether re-
peated SKF-38393 administration to neonate-lesioned rats
would result in enhanced ERK activation in the primary DA-
terminal fields of the forebrain. Immunostaining for phosphor-
ylated (phospho)-ERK revealed distinct temporal patterns in
dorsal striatum (striatum), nucleus accumbens (accumbens),
and cortex. The medial prefrontal cortex (MPC) was unique in
that it demonstrated remarkably sustained phospho-ERK that
was accompanied by increased phospho-CREB immunostaining.
Moreover, the prolonged MPC phospho-ERK immunostaining
was dependent on D1 and NMDA receptor coactivation. Our data
strongly suggest that the sustained ERK phosphorylation ob-
served in MPC reflects a neuroadaptive change that occurs with
D1 agonist-induced sensitization of neonate-lesioned rats.
Materials and Methods
Preparation of neonate 6-OHDA-lesioned rats. Pregnant Sprague Dawley
rats obtained from Charles River Laboratories were individually housed,
with Wayne Lab Blox laboratory chow and water available ad libitum. On
day 3 after delivery, male and female rat pups were anesthetized with
ether and then administered 100 g (free base) of 6-OHDA intracister-
nally (i.c.), 60 min after desipramine (20 mg/kg, i.p.), to protect norad-
renergic neurons (Breese et al., 1984). The bilateral lesion causes 90%
loss of dopamine innervation into the striatum and disrupts basal gan-
glia– cortical system circuits (Smith et al., 1973). Some rats received de-
sipramine (20 mg/kg, i.p.) and saline (i.c.) and served as unlesioned
(sham-lesioned) controls. Rats treated with 6-OHDA or saline neona-
tally were weaned at day 30 and testing began at 40 – 60 d of age. All
animal use procedures were in strict accordance with the Institutional
Animal Care and Use Committee (2003), and all efforts were made to
minimize the number of animals used.
Although several lines of evidence implicate gender differences in the
activation of ERK and CREB (Cardona-Gomez et al., 2002; Bi et al., 2003;
Wade and Dorsa, 2003), no significant SKF-38393-dependent differ-
ences in phospho-ERK or phospho-CREB immunoreactivity were found
between male and female rats, regardless of neonatal lesioning (data not
shown). Thus, SKF-38393-induced phospho-ERK, ERK, phospho-
CREB, or CREB immunoreactivity was examined in the striatum, ac-
cumbens, MPC, and other selected cortical regions of both male and
female rats.
The following sections describe all adult drug treatments, dosing reg-
imens, and times of killing for animals used in this study. Data in sup-
plemental Figure A (available at www.jneurosci.org) are provided as an
additional guide for the experimental paradigm.
Single SKF-38393 treatment to neonate-lesioned adult rats. To assess the
acute effects of a single dose of SKF-38393, naive neonate-lesioned and
sham-lesioned rats were injected with 3 mg/kg SKF-38393 at 40 – 60 d of
age and killed at 15 min (n  4 per treatment group), 30 min (n  4), 60
min (n  4 –5), 120 min (n  5–12), and 360 min (n  2) after agonist
treatment. A separate group of adult neonate-lesioned or sham-lesioned
rats were administered saline, rather than agonist, and killed at 15, 60,
and 120 min to serve as controls (n  2). Neonate-lesioned and sham-
lesioned rats were also killed at 3 d (n  4) and 7 d (n  4 – 6) after this
treatment regimen to examine the long-term effects of a single dose of
agonist to these animals.
Repeated SKF-38393 treatment to neonate-lesioned adult rats. Neonate-
lesioned rats do not show maximal sensitivity to D1 agonists unless ex-
posed repeatedly to such agonists (Breese et al., 1985b; Criswell et al.,
1989). Therefore, beginning at 40 –50 d of age, neonate-lesioned rats in
this treatment group received repeated treatments with SKF-38393 suf-
ficient to allow the animals to reach a plateau of maximal behavioral
supersensitivity (Criswell et al., 1989, 1990). To accomplish this sensiti-
zation process, lesioned animals were administered a total of 12 mg/kg
SKF-38393, divided into three doses as follows: 6, 3, and 3 mg/kg, each
spaced 1 week apart as described previously (Breese et al., 1985a,b;
Criswell et al., 1989). A separate group of sham-lesioned rats received the
same agonist-dosing regimen. To assess acute effects of repeated SKF-
38393 administration, animals were killed at 15 min (n  4 –5 per treat-
ment group), 60 min (n  4 –5), 120 min (n  4), and 360 min (n  2)
after agonist treatment. To serve as controls, groups of neonate-lesioned
and sham-lesioned rats were administered three consecutive injections of
saline at weekly intervals and killed at 15 min (n  2– 4), 60 min (n  2),
120 min (2–3), and 360 min (n  2) after the final saline administration.
To examine the chronic effects of repeated SKF-38393 administration,
animals were killed at 3 d (n  4 – 6), 7 d (n  10 –15), 14 d (n  5– 8),
21 d (n  6 –7), or 36 d (n  5– 6) after the final agonist or saline
treatment. At 36 d, a separate group of previously treated neonate-
lesioned and sham-lesioned rats were administered an additional dose of
SKF-38393 (3 mg/kg) or saline and killed 7 d later (n  5– 6).
Immediately after the final dose of SKF-38393 or saline to neonate-
lesioned or sham-lesioned rats, behavioral activity was assessed to assure
maximal responsiveness of neonate-lesioned rats to the agonist. Rats
were placed in a clear 17  17 inch computer-monitored activity cham-
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ber (Med Associates, St. Albans, VT), and horizontal, vertical, and ste-
reotypical activity was recorded in 5 min bins over a 3 hr testing period.
ANOVA F test of model fit for motor activity between treatment groups
yielded F(3,206)  54.90, p  0.0001 for horizontal activity, F(3,206) 
17.68, p  0.0001 for vertical activity, and F(3,206)  11.94, p  0.0001 for
stereotypical activity. As determined by post hoc analysis using Fisher’s
PLSD test (mean  SEM), neonate-lesioned rats receiving multiple SKF-
38393 treatments demonstrated 120,486.24  10,641.87 total horizontal
counts, 2348.51  263.30 total vertical counts, and 15,167.80  535.27
total stereotypical counts compared with 20,681.32  2357.34 total hor-
izontal counts ( p  0.0001), 799.09  77.84 total vertical counts ( p 
0.0001), and 11,646.37  476.32 total stereotypical counts ( p  0.0001)
observed for neonate-lesioned rats injected with saline, 20,389.82 
2751.24 total horizontal counts ( p  0.0001), 1040.34  118.37 total
vertical counts ( p  0.0001), and 12,371.19  772.15 total stereotypical
counts ( p  0.0026) observed for sham-lesioned rats dosed repeatedly
with SKF-38393, and 20,579.15  1648.53 total horizontal counts ( p 
0.0001), 965.13  71.12 total vertical counts ( p  0.0001), and
10,864.39  579.04 total stereotypical counts ( p  0.0001) observed for
sham-lesioned rats injected with saline. The novelty of the testing envi-
ronment unlikely affected our results, because no significant differences
were found in motor activity between the SKF-38393-sensitized neonate-
lesioned animals and a separate group of neonate-lesioned animals (not
used in this study) that were placed in activity chambers after each of four
weekly treatments with SKF-38393 (supplemental Table A, available at
www.jneurosci.org) ( p  0.4229, horizontal activity; p  0.3034, vertical
activity; p  0.5824, stereotypical activity indicating no difference with
Fisher’s PLSD test). This finding is consistent with previous data accu-
mulated in neonate-lesioned rats showing that behavioral sensitization
results in comparable levels of activity in response to SKF-38393 when
the rats are repeatedly dosed in the same or a different environment from
that in which the rats are finally tested (Criswell et al., 1989).
Pretreatment with the MEK inhibitor SL327 before repeated SKF-38393
administration to neonate-lesioned rats. For this experimental series,
SL327 (-[amino[(4-aminophenyl)thio]methylene]-2-(trifluoromethyl)
benzeneacetonitrile) (100 mg/kg), a selective inhibitor of the upstream
ERK activator MEK, was administered to neonate-lesioned rats 30 min
before each of three weekly doses of SKF-38393 (3 mg/kg), with the
fourth weekly treatment consisting of only dimethylsulfoxide (DMSO)
vehicle followed by SKF-38393 (n  5). Control treatment groups in-
cluded (1) four weekly treatments of DMSO followed by SKF-38393 (n 
4) and (2) four weekly treatments of DMSO followed by saline (n  4).
All rats thus received DMSO before the fourth and final dose of SKF or
saline and were killed 7 d later.
Pretreatment with the D1 antagonist SCH-23390 or the 5-HT2 receptor
antagonist ketanserin before repeated SKF-38393 administration. Groups
of neonate-lesioned and sham-lesioned rats each received four doses of
SCH-23390 (( R)-()-8-chloro-2,3,4,5-tetrahydro-3-methyl-5-phenyl-
1H-3-benzazepine-7-OL maleate; 0.3 mg/kg), ketanserin (3-[2-[4-(4-
fluorobenzoyl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione tar-
trate; 2 mg/kg), or saline 15 min before each of four weekly doses of
SKF-38393 or saline. The primary treatment groups were as follows: (1)
SCH-23390 followed by SKF-38393 (n  6 –10) and (2) ketanserin fol-
lowed by SKF-38393 (n  4). Control treatment groups included (1)
saline followed by SKF-38393 (n  2–10), (2) SCH-23390 followed by
saline (n  2–10), and (3) saline followed by saline (n  4 –5). Rats were
killed 7 d after the final drug treatment.
Pretreatment with NMDA receptor antagonist MK-801 or CGS-19755
before repeated SKF-38393 administration. For the noncompetitive
NMDA receptor antagonist MK-801, male rats were dosed with 0.3 mg/
kg, whereas females received 0.14 mg/kg because female rats have much
greater responsiveness to the motor effects of MK-801 (Fleischmann et
al., 1991; Blanchard et al., 1992; Honack and Loscher, 1993; Haggerty and
Brown, 1996; Frantz and Van Hartesveldt, 1999). MK-801, the com-
petitive NMDA receptor antagonist CGS-19755 (cis-4-(phosphono-
methyl)-2-piperidinecarboxylic acid; 10 mg/kg), or saline was adminis-
tered 15 min before four weekly doses of SKF-38393 (3 mg/kg) or saline.
The two primary treatments were (1) MK-801 followed by SKF-38393
(n  13 per treatment group) and (2) CGS-19755 followed by SKF-38393
(n  6 –18 per treatment group). Control treatments included (1) saline
followed by SKF-38393 (n  5), (2) MK-801 followed by saline (n 
6 – 8), (3) CGS-19755 followed by saline (n  6 –15), and (4) saline
followed by saline (n  7–10). Rats were killed 7 d after the final drug
treatment.
Drugs. 6-OHDA hydrobromide (ICN Biochemicals, Irvine, CA) was
dissolved in saline containing 0.5% ascorbic acid and administered in-
tracisternally. Desipramine hydrochloride (Sigma, St. Louis, MO), SKF-
38393 (Sigma), SCH-23390 (Schering Corporation, Bloomfield, NJ),
ketanserin (Sigma), MK-801 (a gift from Merck, Rahway, NJ), and CGS-
19755 (a gift from CIBA-GEIGY Corporation, Summit, NJ) were dis-
solved in saline and administered intraperitoneally. The MEK inhibitor
SL327 (kindly provided by DuPont Pharmaceuticals Company, Boston,
MA) was dissolved in 100% DMSO and administered intraperitoneally
(2 ml/kg) (Atkins et al., 1998; Selcher et al., 1999; Yamagata et al., 2002).
Immunohistochemistry: tissue preparation and immunostaining. Rats
were deeply anesthetized with an overdose of sodium pentobarbital (100
mg/kg), perfused transcardially for 4 min with PBS (150 mM NaCl, 100
mM sodium phosphate, pH 7.4) followed by 7 min of 4% phosphate–
buffered paraformaldehyde (100 mM sodium phosphate), and their
brains were collected and postfixed for 24 hr at 4°C. Forty-micrometer-
thick sections were then cut with a vibrating microtome for the immu-
nohistochemistry. Standard avidin– biotin– horseradish peroxidase
methods were used as described previously (Knapp et al., 1998, 2001).
After rinsing in fresh PBS three times (10 min each), free-floating tissue
sections were blocked in 10% normal goat serum and 0.2% Triton X-100
in PBS for 1 hr. Affinity-purified polyclonal tyrosine hydroxylase (TH)
(1:4000; Calbiochem, La Jolla, CA), phospho-ERK [phospho-p44/42
MAP kinase (thr202/tyr204); 1:500; Cell Signaling Technology, Beverly,
MA], phospho-CREB, and CREB (both 1:500; Cell Signaling Technol-
ogy) were used to detect protein expression. All sections were incubated
in 3% normal serum, 0.2% Triton X-100, and antisera for 48 –72 hr at
4°C with agitation. An antibody-blocking peptide to phospho-ERK con-
taining phosphorylated amino acid residues threonine 202 and tyrosine
204 (Santa Cruz Biotechnology, Santa Cruz, CA) was used to verify spec-
ificity of the antibody. A 10-fold higher concentration of the blocking
peptide was incubated with phospho-ERK primary antibody at room
temperature for 30 min and then incubated with selected brain tissue as
described above. Tissue sections were further processed using Vectastain
Elite ABC kits (Vector Laboratories, Burlingame, CA) per the manufac-
turer’s instructions with immunochemical detection using nickel-cobalt
intensification of the diaminobenzidine reaction product. For analysis,
great care was taken to match sections through the same region of brain
at the same level. All visible positive nuclei or cell bodies within a 10  10
eyepiece reticule field were counted and expressed as number of cells per
square millimeter of tissue for each brain site. For a single brain site,
counts were averaged from three sections from each animal.
Western blot analysis: tissue preparation and immunoblotting. For
Western blotting, rats were killed by decapitation, their brains were rap-
idly removed from the skulls, and the MPC and striatum were dissected
on ice and stored at 80°C until use. Tissues were homogenized by
sonication in solubilization buffer (10 mM Tris-Cl, 50 mM NaCl, 1%
Triton X-100, 30 mM sodium pyrophosphate, 50 mM NaF, 5 nM ZnCl2,
100 M Na3VO4, 1 mM DTT, 5 nM okadaic acid, 2.5 g aprotinin, 2.5 g
pepstatin, and 2.5 g leupeptin). Insoluble material was removed by
centrifugation (13,000 rpm for 20 min at 4°C), and protein concentra-
tion was determined using a BCA protein assay kit (Pierce, Rockford, IL).
Samples were mixed with Novex 2 Tris-glycine SDS sample buffer (San
Diego, CA) containing 5% 2-mercaptoethanol and heated to 90°C for 3
min. Aliquots of 20 g of protein per lane were separated on 8 –16%
gradient Tris-glycine gels (Novex) under reducing conditions using the
Novex Xcell II minicell apparatus. Proteins were transferred to polyvi-
nylidene difluoride membranes (Immobilon-P, Millipore, Bedford,
MA). Membranes were incubated in PBS with 0.05% Tween 20 (PBS-T),
containing 1% milk powder for 2 hr at room temperature to block non-
specific binding. Blots were probed with an antibody corresponding to
the inactive form of ERK (p44/42 MAPK; 1:1000; Cell Signaling Tech-
nology) or to phospho-ERK (1:1000; Cell Signaling Technology), fol-
lowed by goat anti-rabbit IgG conjugated with horseradish peroxidase
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(Chemicon, Temecula, CA) at a 1:20,000 dilution in blocking solution
for 60 min. Membranes were then washed three times with PBS-T. Bands
were detected using enhanced chemiluminescence (Pierce) apposed to
x-ray film under nonsaturating conditions and analyzed by densitomet-
ric measurements using NIH Image 1.57 (public domain software devel-
oped by the National Institutes of Health and available at http://
rsb.info.nih.gov/nih-image). Data are representative of four animals per
treatment group and normalized on the basis of estimates obtained in the
samples from sham-lesioned, saline-treated controls.
Quantification and statistical analysis. Details of brain region identifi-
cation and cell counting strategy have been reported previously in our
laboratory (Knapp et al., 1998). Average counts for a specific brain region
for each animal were grouped by treatment and averaged for each time
point to obtain the mean counts per square millimeter  SEM for that
brain site. Average cell counts for each defined brain region were com-
pared within and between treatment groups using ANOVA. Statistical
comparisons between control groups versus lesioned groups adminis-
tered either SKF-38393 or saline were followed by post hoc tests. A more
conservative significance level was set at p  0.01 for all time-course
experiments to correct for multiple comparisons, whereas the signifi-
cance level for all other experiments was set at the traditional 0.05 level.
The Fisher’s PLSD test was performed when comparing combinations of
means.
Results
Assessment of dopamine-containing neuronal destruction in
neonate-lesioned adult rats
Previous studies (Smith et al., 1973; Breese et al., 1985a,b) docu-
mented that DA content within the striatum, accumbens, and cortex
is drastically reduced in adult rats lesioned as neonates with
6-OHDA. Such loss of DA-containing terminals in the striatum of
neonate-lesioned rats is illustrated in Figure 1 by the 90% reduc-
tion in TH immunoreactivity compared with the TH level in a sham-
lesioned control animal. Because TH is the rate-limiting enzyme in
the biosynthesis of dopamine (Nagatsu et al., 1964), TH immunore-
activity was determined for all lesioned and control animals in this
investigation to establish that the neonate 6-OHDA lesioning in-
duced an adequate loss of DA-containing neurons.
Acute effects of single and repeated D1 agonist SKF-38393
administration on phospho-ERK immunoreactivity in
neonate-lesioned rats
Phospho-ERK was evaluated in the primary forebrain DA-
terminal regions (i.e., striatum, accumbens, and MPC) of
neonate-lesioned rats at various time points after D1 agonist ad-
ministration. The initial 15 min time point was chosen on the
basis of Gerfen et al. (2002), who demonstrated maximum
phospho-ERK immunoreactivity in striatum of unilateral adult-
lesioned rats 15 min after a single SKF-38393 administration. In
the present study, distinctive patterns of time-dependent ERK
phosphorylation were observed across these brain regions in re-
sponse to SKF-38393.
Striatum and nucleus accumbens
In the striatum, both single and repeated SKF-38393 treatments
to neonate-lesioned rats produced acute, transient increases in
phospho-ERK that peaked at 15 min after drug administration
(Fig. 2A,D,E). Although slightly more phospho-ERK-positive
cells were observed at 15 min in naive neonate-lesioned rats com-
Figure 1. Immunohistochemistry for tyrosine hydroxylase (1:5000; Calbiochem) in coronal
sections representing the striatum, accumbens, and MPC in sham-lesioned and neonate
6-OHDA-lesioned (Lesioned) adult rats.
Figure 2. Administration of the partial D1 agonist SKF-38393 to neonate 6-OHDA-lesioned
rats transiently activates ERK in striatum. A, Time-dependent ERK phosphorylation in striatum
(0 –120 min). Treatment groups are represented by (f) Lesioned SKF  single dose of SKF-
38393 to neonate-lesioned rats; (Œ) Lesioned R-SKF  repeated doses of SKF-38393 to
neonate-lesioned rats; (F) Lesioned Saline  saline treatment to neonate-lesioned rats; ()
Sham SKF  single dose of SKF-38393 to sham-lesioned rats; (‚) Sham R-SKF  repeated
doses of SKF-38393 to sham-lesioned rats; (E) Sham Saline  saline treatment to sham-
lesioned rats. Phospho-ERK-positive cell counts did not significantly differ between rats receiv-
ing single or multiple injections of saline; thus these data were collapsed for each time point
examined. Symbols remain consistent throughout this paper to represent each treatment
group. ANOVA F test of model fit: F(19,74)  9.890; p  0.0001. B, C, At 15 min after SKF-38393
treatment to neonate-lesioned rats, abundant phospho-ERK immunoreactivity is observed in
striatum ( B) but is not present in striatum of neonate-lesioned rats administered saline treat-
ments ( C). D, Representative low-magnification (100) image of phospho-ERK-expressing
cells at 15 min in neonate-lesioned rats administered repeated doses of SKF-38393. E, Neonate-
lesioned rats administered a single dose of SKF-38393. F, Neonate-lesioned rats injected with
saline.
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pared with rats sensitized with the agonist, the difference was not
significant ( p  0.2096). ERK activation was absent in the stria-
tum by 60 min in neonate-lesioned rats administered a single
dose of SKF-38393; however, phospho-ERK immunoreactivity
remained significantly elevated at this time point in rats admin-
istered repeated doses of SKF-38393 ( p  0.0001). This prolon-
gation of ERK phosphorylation appeared to occur most promi-
nently in the dorsomedial and dorsolateral quadrants of the
striatum, with lighter staining occurring ventrally (Fig. 2B).
Phospho-ERK was no longer detected at 120 min in striatum of
SKF-38393-treated neonate-lesioned rats. No phospho-ERK im-
munoreactivity was detected in striatum of neonate-lesioned rats
treated with saline or in sham-lesioned rats treated with single or
repeated doses of SKF-38393 or saline at any of the time points
examined (Fig. 2A,C,F).
In accumbens, a single dose of SKF-38393 to drug-naive
neonate-lesioned animals or controls failed to produce signifi-
cant change in phospho-ERK at any time point (Fig. 3A,C,E,F).
Neonate-lesioned rats administered repeated doses of SKF-
38393, however, exhibited significant phospho-ERK immunore-
activity at acute time points before 120 min (Fig. 3A,B,D) com-
pared with neonate-lesioned animals administered saline ( p 
0.0001, 15 min; p  0.0001, 60 min). This enhanced ERK phos-
phorylation was observed specifically in the rostral pole of the
accumbens and was not present in the caudal shell or core of
neonate-lesioned rats receiving repeated doses. Although the
time course of accumbens phospho-ERK immunoreactivity was
similar to that of striatum, total phospho-ERK-positive cell
counts in the accumbens were 20 – 40% of striatum, and the
intensity of phospho-ERK immunostaining in the accumbens
was much lower. It is unlikely that these effects were artifacts of
tissue processing, because representative sections of the striatum
and accumbens were always stained concurrently.
Medial prefrontal cortex
A baseline of 18 –25 phospho-ERK-positive cells per square
millimeter was observed consistently in MPC and did not signif-
icantly differ among the sham or saline-treated lesioned groups
(Fig. 4A). Neonate-lesioned rats that received a single dose of
SKF-38393 demonstrated a transient (0 – 60 min) increase in
ERK phosphorylation over baseline in MPC, which was similar in
profile and duration to the striatum of these animals (compare
Figs. 2A, 4A). Phospho-ERK immunoreactivity in this treatment
group was significantly elevated over control groups only at 15
min after agonist administration ( p  0.0001 for Lesioned SKF
vs control groups).
Among the dopamine-rich regions, MPC displayed a unique,
highly prolonged increase in phospho-ERK in neonate-lesioned
rats previously administered repeated doses of SKF-38393. In
these animals, phospho-ERK-immunoreactive cell counts were
increased four- to sixfold, primarily within layers II–III of the
MPC. These phospho-ERK-positive counts remained elevated
over the course of the examination (up to 360 min) (Fig. 4A–H)
( p  0.0085 at 15 min, p  0.0015 at 60 min, p  0.0001 at 120
min for Lesioned R-SKF vs Lesioned SKF groups; p  0.01 at 15,
60, and 120 min, and p  0.02 at 360 min for Lesioned R-SKF vs
other control groups). The conspicuous persistence of ERK hy-
perphosphorylation in MPC, but not in striatum or accumbens,
suggests that different processes of neuroadaptation occur
among these brain regions and, furthermore, that the adaptive
changes occurring in the MPC are more enduring.
Sustained duration of ERK phosphorylation in MPC of
neonate-lesioned rats after repeated
SKF-38393 administration
Because the persistent increase in ERK phosphorylation was ob-
served for up to 360 min in MPC of neonate-lesioned rats sensi-
tized with SKF-38393, an additional evaluation of the time course
of the sustained ERK response in this region was performed. As
shown in Table 1, control groups did not significantly differ from
each other across time points, with phospho-ERK-positive cell
counts remaining at the baseline level of 18 –25 cells per square
millimeter. Neonate-lesioned rats sensitized with repeated doses
of SKF-38393 demonstrated a sustained increase in phospho-
ERK immunoreactivity in MPC that was significantly elevated
over neonate-lesioned rats injected with saline (as well as sham-
lesioned control groups) across all extended time points ( p 
0.0001 at 3, 7, and 14 d; p  0.0109 at 21 d; p  0.0025 at 36 d
comparing R-Saline and R-SKF groups). Prominent phospho-
ERK in MPC of these animals persisted for 7 d after the final
agonist treatment (Table 1). Beyond 7 d, sensitized phospho-
ERK immunoreactivity began to diminish, yet remained
significantly elevated from that observed in saline-treated
Figure 3. Repeated administration of the partial D1 agonist SKF-38393 to neonate 6-OHDA-
lesioned rats transiently increases phospho-ERK in accumbens. A, Time-dependent phospho-
ERK immunoreactivity in accumbens (0 –120 min). ANOVA F test of model fit: F(19,74)  27.335;
p  0.0001. B, C, At 15 min, phospho-ERK immunostaining is observed in accumbens of
neonate-lesioned rats administered repeated doses of SKF-38393 ( B) but is not present in
accumbens of neonate-lesioned rats administered only a single dose of SKF-38393 ( C). D, Rep-
resentative low-magnification (100) image of phospho-ERK-expressing cells at 15 min in
neonate-lesioned animals administered repeated doses of SKF-38393. E, Neonate-lesioned rats
administered a single dose of SKF-38393. F, Neonate-lesioned rats injected with saline. *p 
0.01 with Fisher’s PLSD test. Scale bar, 250 m.
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neonate-lesioned and sham-lesioned rats for
up to 36 d ( p  0.01 for all comparisons).
As shown in Table 1, an additional dose
of SKF-38393 administered at 36 d to pre-
viously sensitized neonate-lesioned rats
resulted in significantly elevated levels of
phospho-ERK immunoreactivity 7 d later
(i.e., at 42 d) compared with levels ob-
served at 36 d ( p  0.0001). Phospho-
ERK-positive cell counts in these animals
were nearly identical to those found in
neonate-lesioned rats killed 3 and 7 d after
the initial SKF-38393 dosing regimen
( p  0.1110, indicating no significant dif-
ference). In neonate-lesioned rats injected
repeatedly with saline, an additional dose
of saline at 36 d did not result in elevated
phospho-ERK immunoreactivity at 7 d af-
ter injection (data not shown), nor did a
single dose of SKF-38393 to neonate-
lesioned or sham-lesioned rats (Table 1).
Sham-lesioned rats that received saline
treatment at 36 d also did not exhibit a
significant increase in phospho-ERK im-
munoreactivity at 7 d after injection (data
not shown).
To ascertain that the observed immu-
nohistochemical staining was phospho-
ERK and not another phosphoprotein or
nonspecific reaction, immunoblotting was
performed with protein isolated from
MPC of lesioned rats administered re-
peated doses of SKF-38393 or injected
with saline (data not shown). Blots probed
with the same concentration of phospho-
ERK antibody used for immunohisto-
chemistry revealed the typical doublet of
bands near 42 and 44 kDa related to
phospho-ERK1 and phospho-ERK2, re-
spectively. No other bands were visualized,
a finding that provides strong evidence
that the elevated immunohistochemical
staining observed in MPC of rats dosed re-
peatedly with SKF-38393 was specific for
phospho-ERK.
A plausible explanation for our find-
ings with sustained phospho-ERK would
be that total ERK protein levels were el-
evated chronically in the neonate-le-
sioned animals after repeated exposure
to SKF-38393. Therefore, we examined
whether sensitization of neonate-le-
sioned rats to SKF-38393 would produce
long-lasting changes in total ERK protein in MPC. Because
immunohistochemistry for unphosphorylated ERK failed to
produce a consistent signal, total ERK protein was analyzed by
SDS-PAGE and immunoblotting of equally loaded total pro-
teins from MPC and striatum (blot not shown). No significant
differences were found for optical density measurements
(mean  SEM) of total ERK levels among neonate-lesioned
rats repeatedly dosed with SKF-38393 (MPC, 101.86  5.42;
striatum, 91.0  5.59), sham-lesioned rats repeatedly dosed
with SKF-38393 (MPC, 95.60  4.75; striatum, 91.56  1.96),
saline-treated neonate-lesioned rats (MPC, 105.30  3.30;
striatum, 94.00  1.12), or saline-treated sham-lesioned rats
(MPC and striatum standardized to 100%) at day 7 after the
final injection of agonist (ANOVA F test of model fit: F(3,12) 
1.040, p  0.4102 for MPC; F(3,12)  1.865, p  0.1893 for
striatum). Because total ERK levels were not changed by the
repeated D1 agonist treatments in neonate-lesioned rats, the
sustained increase in phospho-ERK immunoreactivity in
MPC could not be attributed to a sustained increase in total
ERK protein.
Figure 4. Repeated administration of the partial D1 agonist SKF-38393 to neonate-lesioned rats produces a sustained increase
in ERK phosphorylation in MPC. A, Time-dependent phospho-ERK immunoreactivity (0 –360 min). ANOVA F test of model fit:
F(23,79)  12.943; p  0.0001. B, Neonate-lesioned rats administered repeated doses of SKF-38393 demonstrated robust
phospho-ERK immunostaining at 120 min. C, C	, Representative low-magnification (100) ( C) and high-magnification (400)
(C	) images of phospho-ERK-expressing cells (120 min) in neonate-lesioned rats administered repeated doses of SKF-38393. D,
Increased phospho-ERK immunostaining was not present at 120 min in MPC of neonate-lesioned rats administered a single dose
of SKF-38393. E, E	, Representative low-magnification (100) ( E) and high-magnification (400) (E	) images of phospho-ERK-
expressing cells (120 min) in neonate-lesioned rats administered a single dose of SKF-38393. F, Neonate-lesioned rats adminis-
tered repeated saline injections. G, Sham-lesioned rats administered repeated doses of SKF-38393. H, Corresponding blocking
peptide inhibited sustained phospho-ERK immunoreactivity in neonate-lesioned rats repeatedly dosed with SKF-38393. *p 
0.01 with Fisher’s PLSD test. Scale bar, 250 m.
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Sustained duration of ERK phosphorylation in other cortical
regions of neonate-lesioned rats after repeated
SKF-38393 administration
Because of the extraordinarily sustained phospho-ERK response
observed in MPC, we examined other cortical areas of neonate-
lesioned rats dosed repeatedly with agonist to determine whether
ERK phosphorylation was prolonged in these regions. (Fig. 5,
Table 2). Phospho-ERK immunostaining was elevated in ventro-
lateral orbital cortex (VLOC) and in layer II–III cells of cingulate
(CgC), motor (MC), somatosensory (SSC) and piriform (PirC)
cortices when examined at day 7 after the final agonist treatment.
As shown in Table 2, levels of phospho-ERK immunoreactivity
for each cortical region were significantly higher at day 7 than
levels observed at days 14 –21 and 36 after the agonist treatment
( p  0.01 for all comparisons). Levels at day 7 after agonist
treatment were also significantly higher than levels observed at all
time points in saline-treated neonate-lesioned rats and sham-
lesioned controls for each cortical region examined (Fig. 5) ( p 
0.01 for all comparisons). Although apparent phospho-ERK-
positive cell counts were still elevated (although not statistically
significant) at 14 –21 d after repeated agonist treatment,
phospho-ERK in these cortical regions was clearly reduced by day
36. An additional dose of SKF-38393 at day 36 restored some
phospho-ERK immunoreactivity in these cortical regions when
examined 7 d later, but these levels were not significantly different
from levels observed at day 36 before the additional dose (Table
2). Likewise, these levels were not different from those observed
in saline-treated neonate-lesioned rats killed at day 36 or in
saline-treated neonate- or sham-lesioned rat groups adminis-
tered a single dose of SKF-38393 at day 36 and killed 7 d after
injection (data not shown). In contrast to cortex, neither the
striatum nor the accumbens of SKF-38393-sensitized rats exhib-
ited phospho-ERK immunoreactivity at 7 d after the final sensi-
tizing dose of agonist (Fig. 5).
Together, these data demonstrate that sustained phospho-
ERK immunoreactivity occurs in multiple areas of the cortex, but
not in the striatum or accumbens, of D1 agonist-sensitized
neonate-lesioned rats. These changes are most remarkable in
MPC, where ERK phosphorylation lingers longest and remains
most sensitive to full reinstatement with an additional dose of
agonist. That the ERK pathway could respond to repeated D1
agonist stimulation in such a prolonged and regionally selective
manner suggests that specific neuroadaptive changes accompany
D1 sensitization in the neonate-lesioned rat. With respect to the
MPC, neuroadaptive changes in this region are thought to play a
role in diseases related to dopaminergic dysfunction such as
schizophrenia, attention-deficit– hyperactivity disorder, and
drug abuse (Laruelle, 2000; Vanderschuren and Kalivas, 2000;
Steketee, 2003; Sullivan and Brake, 2003). Because behavioral
alterations in the neonate-lesioned rat have been suggested to
model each of these diseases (Schwarzkopf et al. 1992; Stevens et
al., 1996; Fahlke and Hansen 1999; Moy and Breese 2002; Davids
et al., 2003), we chose to focus most of the remainder of our study
on exploring this phenomenon in the MPC.
Sustained CREB phosphorylation in MPC associated with
prolonged phospho-ERK in neonate-lesioned rats after
repeated SKF-38393 administration
Phosphorylation of ERK can activate the transcription factor
CREB to affect long-term gene expression (Lonze and Ginty,
2002). Thus, phosphorylated CREB potentially represents a func-
tional product of the sustained ERK response after repeated dos-
ing with SKF-38393 to neonate-lesioned rats. When sections
from the same animals were immunostained concurrently, we
Table 1. Chronic time course of ERK phosphorylation in MPC after repeated doses of SKF-38393 or saline to neonate- and sham-lesioned rats (mean  SEM)
Time of killinga Lesioned R-Saline Lesioned R-SKF Sham R-Saline Sham R-SKF
ERK phosphorylation at extended time points after SKF-38393 treatment
3 d 18.42  7.29 94.38  4.63*† 30.08  4.77 27.50  5.38
7 d 19.90  5.95 114.40  13.37*† 18.15  5.60 16.80  2.70
14 d 19.30  5.95 53.59  4.30*‡ 19.17  3.06
21 d 22.78  3.10 42.43  7.24*‡ 25.42  2.64
36 d 17.10  3.70 37.25  2.55* 15.00  4.00
ERK phosphorylation after reinstatement dose of SKF-38393 at 36 d
7 d after additional treatmentb 28.08  4.88 96.10  2.36*† 18.50  10.26
ANOVA F test of model fit: F(19,117)  16.057; p  0.0001. Cells were counted at 100 magnification.
aInterval between repeated SKF-38393 or saline treatment and killing.
bRats were killed at day 42, 7 d after an additional dose of SKF-38393 at 36 d.
*Counts are significantly different from all other counts (across all treatment groups and time points) at the p  0.01 significance level with Fisher’s PLSD test.
†,‡Counts within a treatment group (column) significantly differ from each other at the p  0.01 significance level with Fisher’s PLSD test.
Table 2. Chronic time course of ERK phosphorylation in various cortical regions after repeated doses of SKF-38393 to neonate-lesioned rats (mean  SEM)
Time of killinga
Brain region 7 d 14 –21 db 36 d 7 d after additional dose at 36 d (42 d)c
VLOC 53.21  14.86* 29.53  7.49 16.50  7.27 39.83  17.32
CgC 50.58  10.28* 19.91  4.18 7.90  3.30 28.00  9.88
MC 106.08  20.05* 49.44  9.60 15.10  3.80 47.07  18.06
SSC 113.96  23.44* 37.19  7.99 25.50  8.86 62.07  23.23
PirC 135.5  28.75* 53.84  7.82 28.90  9.82 64.07  15.91
ANOVA F test of model fit: VLOC, F(7,65) 2.863, p0.0115; CgC, F(7,65) 5.551, p0.0001; MC, F(7,65) 5.681, p0.0001; SSC, F(7,65) 6.960, p0.0001; PirC, F(7,65) 6.090, p0.0001. Cells were counted at 100magnification
for each region.
aInterval between repeated SKF-38393 or saline treatment and killing.
bValues at 14 –21 d did not significantly differ within treatment groups for each cortical region examined and thus collapsed.
cRats were killed at day 42, 7 d after an additional dose of SKF-38393 at 36 d.
*Counts within a given cortical region are significantly different from all other counts in that region at the p  0.01 significance level, except for Lesioned R-SKF 7 d versus Lesioned-R-SKF 42 d in VLOC.
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observed a robust increase in phospho-CREB immunoreactivity
accompanying phospho-ERK in MPC at day 7 after repeated
SKF-38393 administration (Fig. 6A). To our surprise, however,
increased phospho-CREB immunoreactivity was observed not
only in layers II–III, but throughout all MPC layers (Fig. 6B,F).
When quantified across all MPC layers, neonate-lesioned ani-
mals repeatedly dosed with SKF-38393 demonstrated approxi-
mately a four- to fivefold increase in phospho-CREB-positive cell
counts (mean  SEM; 795.07  137.81) compared with neonate-
lesioned rats injected repeatedly with saline (146.50  40.28; p 
0.0001) and sham-lesioned rats treated repeatedly with SKF-
38393 (127.13  12.21; p  0.0002) or saline (226.42  78.00;
p  0.0003). Cell counts specifically in layers II–III in the agonist-
sensitized rats exhibited nearly a ninefold increase in phospho-
CREB-positive cell counts compared with control animals (Fig.
6A) ( p  0.0001 for Lesioned R-SKF vs Lesioned R-Saline, Sham
R-SKF, or Sham R-Saline). The elevation in number of phospho-
CREB-positive cells was not reflective of increased total CREB
protein expression (mean values  SEM were 343.75  8.68 for
Lesioned R-SKF, 319.67  8.56 for Lesioned R-Saline, and
329.38  16.55 for Sham R-Saline; ANOVA F test of model fit:
F(2,13)  1.475; p  0.265). Notably, only scattered phospho-
CREB-positive cells were noted throughout the striatum and ac-
cumbens at day 7, regardless of drug treatment (Fig. 6H, I). Sus-
tained CREB phosphorylation was not observed in any other
cortical regions examined (ANOVA F test of model fit: F(3,19) 
1.181, p  0.345 for VLOC; F(3,19)  0.575, p  0.639 for CgC;
F(3,19)  1.086, p  0.380 for MC; F(3,19)  1.051, p  0.394 for
SSC; and F(3,19)  0.506, p  0.683 for PirC). Thus phospho-
CREB immunolabeling, unlike phospho-ERK, was restricted to
MPC. Furthermore, the multilamellar expression of phospho-
CREB did not mirror the predominant appearance of phospho-
ERK in layers II–III, suggesting that some, although perhaps not
all, of the phospho-CREB immunolabeling was caused by mech-
anisms other than activation of ERK.
Effect of MEK-inhibitor (SL327) pretreatment on sustained
ERK and CREB phosphorylation in MPC of neonate-lesioned
rats after repeated administration of SKF-38393
The involvement of MEK in sustained ERK phosphorylation was
demonstrated using systemic injections of SL327, a MEK inhibi-
tor that crosses the blood– brain barrier (Atkins et al., 1998;
Selcher et al., 1999; Yamagata et al., 2002). Phospho-ERK immu-
noreactivity was suppressed in neonate-lesioned rats pretreated
with SL327 before each SKF-38393 administration, compared
with those pretreated with vehicle (Fig. 7A–C) ( p  0.0001). The
number of phospho-ERK-positive cells in SL327-pretreated rats
did not differ significantly from rats treated with vehicle alone.
These data provide further evidence that the elevated immuno-
staining of MPC cells observed in SKF-38393-sensitized neonate-
lesioned rats is indeed represented by MEK-dependent ERK
phosphorylation.
We also examined the effects of SL327 pretreatment on
phospho-CREB immunolabeling in MPC. Phospho-CREB im-
munoreactivity was reduced to some extent throughout all layers
of MPC by pretreatment with SL327 (Fig. 7D,F) ( p  0.0238 for
SL R-SKF vs R-SKF). The most dramatic suppression of
phospho-CREB immunoreactivity by the MEK inhibitor, how-
ever, was produced in layers II–III (Fig. 7D–F) ( p  0.0001 for SL
R-SKF vs R-SKF), in which cell counts did not significantly differ
from rats that were not given the agonist-sensitizing regimen.
These findings are consistent with direct involvement of both
MEK and ERK activation in sustained CREB phosphorylation in
Figure 5. Photomicrographs depicting ERK phosphorylation in various cortical regions, stri-
atum, and accumbens of neonate-lesioned rats at day 7 after repeated SKF-38393 administra-
tion (R-SKF) or saline treatment. VLOC, Ventrolateral orbital cortex, orbitofrontal cortex; CgC,
Cg1, and Cg2, cingulate cortex; MC, M1, and M2, motor cortex; SSC, S1, somatosensory cortex;
PirC, piriform cortex; STR, striatum; NAC, accumbens. Scale bar, 100 m.
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Figure 6. Repeated administration of SKF-38393 to neonate-lesioned rats produces long-
lastingCREBphosphorylationinMPC.A,Graphicrepresentationof layers II–IIIphospho-CREB-positive
cell counts in MPC at day 7 after repeated SKF-38393 or saline treatment to neonate-lesioned (solid
bars)orsham-lesioned(stripedbars)rats.*p0.05withFisher’sPLSDtest.R-SKF,Ratsadministered
repeated doses of SKF-38393; R-Saline, rats injected repeatedly with saline. ANOVA F test of model fit:
F(3,28)82.148; p0.0001. B, C, Robust phospho-CREB immunostaining is observed only in MPC of
neonate-lesioned rats at day 7 after repeated SKF-38393 administration ( B) but not in MPC of
neonate-lesioned rats treated with saline rather than the agonist ( C). D, E, Only scattered phospho-
CREB-positive cells were noted in striatum and accumbens of neonate-lesioned rats administered
repeated SKF-38393 administration ( D) and neonate-lesioned rats injected with saline ( E). F, G, Rep-
resentative low-magnification (100) images of phospho-CREB-immunoreactive cells in MPC of
neonate-lesioned rats dosed repeatedly with SKF-38393 ( F) or saline ( G). Scale bar, 250 m. H, I,
Representative high-magnification (200) images of phospho-CREB immunoreactive cells in stria-
tum of neonate-lesioned rats dosed repeatedly with SKF-38393 (H) or saline ( I ). Scale bar, 50 m.
Figure 7. Sustained ERK and CREB phosphorylation is blocked by pretreatment with MEK
inhibitor SL327 before each weekly dose of SKF-38393. A, Graphic representation of phospho-
ERK-positive cell counts in MPC at day 7 after drug treatment. Vehicle, Neonate-lesioned rats
pretreated with vehicle (DMSO) before weekly saline injections; R-SKF, neonate-lesioned rats
administered vehicle before SKF-38393 treatment; SL R-SKF, neonate-lesioned rats pretreated
with SL327 before SKF-38393 treatment. ANOVA F test of model fit: F(2,10)  40.604; p 
0.0001. B, C, Representative low-magnification (100) images of phospho-ERK-
immunoreactive cells in R-SKF ( B) and SL R-SKF ( C) treatment groups. D, Graphic representa-
tion of phospho-CREB-positive cell counts across all layers (solid bars) and only layers II–III
(striped bars) of MPC after pretreatment with SL327 before each weekly dose of SKF-38393.
ANOVA F test of model fit: F(2,10)  35.82; p  0.0001. E, F, Representative low-magnification
(100) image of phospho-CREB immunoreactive cells in R-SKF ( E) and SL R-SKF ( F) treatment
groups. Note that SL327 pretreatment appeared to reduce phospho-CREB-positive cell counts
primarily in layers II–III of MPC, where sustained phospho-ERK immunoreactivity is most prom-
inent. *p  0.05 with Fisher’s PLSD test. Scale bar, 250 m.
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layers II–III, but perhaps indirect, if any, involvement in CREB
phosphorylation in deeper layers.
Inhibition of sustained SKF-38393-induced ERK
phosphorylation in MPC of neonate-lesioned rats after
pretreatment with the D1 antagonist SCH-23390
To determine whether the sustained phospho-ERK observed in
MPC of neonate-lesioned rats sensitized with SKF-38393 was
dependent on D1 receptors, rats were pretreated with the D1 an-
tagonist SCH-23390. As shown in Figure 8, A and C, SCH-23390
pretreatment to neonate-lesioned rats abrogated phospho-ERK
immunoreactivity at this brain site ( p  0.0001 compared with
Lesioned R-SKF group). The number of phospho-ERK-positive
cells for this treatment group did not differ significantly from
neonate-lesioned rats administered repeated saline injections or
from sham-lesioned control groups. Moreover, repeated SCH-
23390 treatment on its own did not enhance phospho-ERK im-
munoreactivity in either neonate-lesioned or sham-lesioned rats.
Rats were also pretreated with the 5-HT2 receptor antagonist
ketanserin to control for the antagonist binding properties of
SCH-23390 at 5-HT2 receptors (Fig. 8A) (Bischoff et al., 1988;
McQuade et al., 1988). Ketanserin was ineffective at reducing the
persistently increased levels of phospho-ERK ( p  0.578 com-
pared with Lesioned R-SKF group), indicating that the prolonged
phospho-ERK observed in MPC of SKF-38393-sensitized
neonate-lesioned rats is dependent on activation of D1 receptors.
NMDA receptor blockade prevents the sustained ERK
phosphorylation in MPC induced by repeated doses of SKF-
38393 to neonate-lesioned rats
Previous work in our laboratory has demonstrated that MK-801
inhibits SKF-38393-induced behavioral sensitization of neonate-
lesioned rats, a finding that implicates NMDA receptor function
in adaptive processes underlying repeated SKF-38393 treatment
to these animals (Criswell et al., 1990). In the present study, ad-
ministration of MK-801 or CGS-19755 to neonate-lesioned and
sham-lesioned animals before repeated injections of saline had
no effect on basal phospho-ERK immunoreactivity (Fig. 9E). On
the other hand, pretreatment with MK-801 or CGS-19755 before
repeated doses of SKF-38393 to neonate-lesioned rats resulted in
marked inhibition of sustained phospho-ERK immunoreactivity
in MPC (Fig. 9A,C) ( p  0.0001 for Lesioned MK-801 R-SKF
group vs Lesioned R-SKF group, and for Lesioned CGS R-SKF
group vs Lesioned R-SKF group). Consequently, these data point
to an involvement of NMDA receptors in the sustained phospho-
ERK response in MPC of neonate-lesioned animals.
Discussion
This study demonstrates the remarkably protracted course of
ERK phosphorylation in MPC and other cortical regions of neo-
nate 6-OHDA-lesioned rats behaviorally sensitized to the effects
of a D1 agonist in adulthood. Our observations suggest that pro-
longed MPC phospho-ERK is a neurobiological substrate of
long-lasting adaptive change in these animals, as indicated by
several key findings. First, MPC is unique among cortical and
striatal regions, in that sustained ERK phosphorylation observed
primarily in layers II–III declined gradually, yet remained signif-
icantly above control levels for at least 36 d. Second, maximal
levels of phospho-ERK were restored fully in MPC, but not sig-
nificantly in other cortical areas, on day 42 after an additional
dose of agonist on day 36. Furthermore, an analogous increase in
phospho-CREB in layers II–III of MPC, but not other cortical
regions, at 7 d after the initial sensitizing regimen was MEK de-
pendent. This finding suggests that a functional effect of sus-
tained MPC ERK phosphorylation is activation of CREB-
dependent gene transcription. Finally, the development of
sustained phospho-ERK in MPC requires both NMDA and D1
receptor stimulation, a pattern of dependence resembling that
identified in several cellular and behavioral neuroadaptive para-
digms that have been described in cortical and striatal systems
(for review, see Kelley and Berridge, 2002). These findings, to-
gether with the proposed contribution of the MPC in the progres-
sive and enduring behavioral effects of drugs of abuse (Castner
and Goldman-Rakic, 2003; Steketee 2003), schizophrenia (Laru-
elle, 2000; Tzschentke, 2001), and learning and memory (Castner
et al., 2000; Elzinga and Bremner, 2002), suggest that the D1
agonist-sensitized neonate-lesioned rat presents an excellent
model for the study of dopamine-dependent neuroadaptations
and their functional consequences.
Several studies have demonstrated that activation of D1 recep-
tors, via a protein kinase A (PKA)-dependent mechanism, can
phosphorylate ERK to produce adaptive changes in brain
(Vossler et al., 1997; Yao et al., 1998; York et al., 1998; Valjent et
al., 2000). In unilateral adult 6-OHDA-lesioned rats, Gerfen et al.
(2002) demonstrated transient ERK activation in striatum after
Figure 8. Sustained ERK phosphorylation is blocked by pretreatment with D1 antagonist
SCH-23390 but not with 5-HT2 antagonist ketanserin. A, Graphic representation of phospho-
ERK-positive cell counts in MPC of neonate-lesioned (solid bars) and sham-lesioned (striped
bars) treatment groups at day 7 after drug treatment. R-SKF, Rats administered saline before
SKF-38393; SCH R-SKF, rats pretreated with SCH-23390 before SKF-38393; Ketanserin R-SKF,
rats pretreated with ketanserin before SKF-38393; SCH R-Saline, rats pretreated with SCH-
23390 before saline injection; R-Saline, rats pretreated with saline (vehicle) before saline injec-
tion. ANOVA F test of model fit: F(8,44)  22.434; p  0.0001. B, C, Representative low magni-
fication (100) images of phospho-ERK immunoreactive cells in R-SKF ( B) and SCH R-SKF ( C)
neonate-lesioned rat groups. *p  0.05 with Fisher’s PLSD test. Scale bar, 250 m.
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acute D1 agonist administration, an effect attributed to sensitized
D1 receptor-dependent responses. Consistent with this finding,
the present study demonstrates a transient phosphorylation
(60 min) of ERK induced by a single dose of SKF-38393 in
drug-naive neonate-lesioned rat striatum and MPC. Notably, the
pattern and duration of ERK phosphorylation in striatum of na-
ive neonate-lesioned rats administered a single dose of SKF-
38393 were similar to that published by Gerfen et al. (2002) in
unilateral adult 6-OHDA-lesioned rats. In agreement with the
transient ERK phosphorylation, previous work has shown that a
single dose of SKF-38393 can induce Fos expression in striatum
of neonate-lesioned rats (Johnson et al., 1992). Together with the
findings of Sgambato et al. (1998) and Gerfen et al (2002), it
appears that transient ERK activation can drive immediate-early
gene induction in striatum. It remains a question whether tran-
sient phospho-ERK observed in the striatum and MPC of
neonate-lesioned rats after a single dose of SKF-38393 is suffi-
cient to drive long-term gene regulation.
Several lines of evidence suggest that prolonged ERK activa-
tion (60 min) is necessary to allow sufficient time for translo-
cation of ERK to the nucleus, long-term gene transcription, and
subsequent enhancement of enduring plasticity-associated
changes in brain (for review, see Marshall, 1995). Repeated D1
agonist administration prolonged striatal phospho-ERK immu-
noreactivity nearly twofold. Conversely, in accumbens, ERK ac-
tivation was absent with a single dose of agonist and was observed
only after repeated treatment with SKF-38393. These findings,
together with the prolonged presence of ERK phosphorylation in
the MPC and various other regions of cortex (VLOC, CgC, MC,
SSC, and PirC), point to differing mechanisms of adaptation
among these regions. Furthermore, the reinstatement of ERK
phosphorylation that occurs only in MPC supports a unique
mechanism of adaptation in this region that can trigger rapidly
the previous level of ERK activation on reexposure to the agonist.
A well characterized nuclear target for ERK action is the tran-
scription factor CREB (Bourtchuladze et al., 1994; Yin et al.,
1994), which is thought to play a central role in long-term plastic
changes in brain by controlling the transcriptional expression of
several genes (for review, see Curtis and Finkbeiner, 1999). In the
present study, immunostaining for phospho-CREB was mea-
sured initially as a functional endpoint for sustained ERK activa-
tion in MPC. Surprisingly, although phospho-CREB emerged in
parallel with ERK phosphorylation in layers II–III, the popula-
tion of immunolabeled cells was more dense and widespread than
those labeled with anti-phospho-ERK. In fact, phospho-CREB
immunoreactivity appeared throughout all layers of MPC. At this
time, we can only speculate as to the reasons for this seeming
incongruence. One obvious possibility is that mechanisms inde-
pendent of ERK drive CREB phosphorylation. Although
phospho-CREB in layers II–III was sensitive to the MEK (and
thus ERK) activation state, labeling in the deeper layers of MPC
was less responsive to MEK inhibition. Because CREB is a com-
mon substrate of multiple kinase pathways in cell model systems
(for review, see Herdegen and Leah, 1998; Curtis and Finkbeiner,
1999), other pathways, such as the PKA, CaM kinase, and stress-
activated protein kinase cascades, might be responsible for the
phospho-CREB effect. Another possibility could be related to
functional integration of phospho-ERK-expressing neurons with
nonexpressing cells, whereupon ERK-dependent activity in a
small population of MPC layer II–III neurons could influence
activation, signaling, and appearance of phospho-CREB in corti-
cal and subcortical cells beyond simply those that contain
phospho-ERK. The mild reduction in phospho-CREB immuno-
reactivity observed throughout all MPC layers after MEK inhibi-
tion would seem to support a mechanism involving intercellular
integration. Nevertheless, additional studies are necessary to
resolve these complex issues.
Several lines of evidence suggest that sustained ERK activation
may be indicative of neuronal insult, possibly leading to cell death
(Stanciu et al., 2000; Kulich and Chu, 2001). Prolonged ERK
activation in neurodegenerative processes has been linked to de-
creased CREB activation (Lee et al., 2002; Trentani et al., 2002).
In the present study, sustained ERK phosphorylation in MPC was
accompanied by increased, rather than decreased, CREB phos-
phorylation. On the opposite end of the spectrum, prolonged
ERK activation accompanied by an increase in CREB has been
linked to a continuum of processes that include cell survival and
plasticity (Shen et al., 2001; Sweatt, 2001; Dawson and Ginty,
Figure 9. Sustained ERK phosphorylation is blocked by pretreatment with NMDA receptor
antagonists MK-801 and CGS-19755 before each repeated weekly dose of SKF-38393. A,
Graphic representation of phospho-ERK-positive cell counts in neonate-lesioned (solid bars)
and sham-lesioned (striped bars) treatment groups at day 7 after drug treatment. R-SKF, Rats
administered saline before SKF-38393; MK-801 R-SKF, rats pretreated with MK-801 before
SKF-38393; CGS R-SKF, rats pretreated with CGS-19755 before SKF-38393; MK-801 R-Saline,
rats pretreated with MK-801 before saline injection; CGS R-Saline, rats pretreated with CGS-
19755 before saline injection; R-Saline, rats pretreated with saline (vehicle) before saline injec-
tion. ANOVA F test of model fit: F(11,100)  10.206; p  0.0001. B–E, Representative low-
magnification (100) images of phospho-ERK immunoreactive cells in R-SKF ( B), in MK-801
R-SKF ( C), in CGS R-SKF ( D), and in MK-801 R-Saline ( E) neonate-lesioned rat groups. *p0.05
with Fisher’s PLSD test. Scale bar, 250 m.
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2002). Thus, it appears that the precise kinetics of ERK and CREB
phosphorylation can ultimately determine the fate of a cell within
a given region. Although neurodegenerative processes cannot be
ruled out, we speculate that the sustained increases in ERK and
CREB phosphorylation observed herein are likely to be indicative
of cell survival and plasticity in MPC.
The sustained increase in phospho-ERK was dependent on D1
receptor function, because SCH-23390 antagonist pretreatment
blocked the prolonged response to repeated administration of the
D1-selective partial agonist SKF-38393. It is unlikely that SCH-
23390 inhibited prolonged ERK phosphorylation through its in-
teraction with 5-HT2 binding sites (Bischoff et al., 1988; Mc-
Quade et al., 1988), because systemic injections of the
nonselective 5-HT2 antagonist ketanserin, before repeated doses
of SKF-38393, had no effect on the sustained phospho-ERK re-
sponse in MPC. In addition, the results with ketanserin further
support the notion that long-lasting ERK phosphorylation does
not drive expression of locomotor responsiveness to D1 agonists
in SKF-38393-sensitized animals. The spontaneous hyperactive
behavior of neonate-lesioned animals has been linked to seroto-
nergic mechanisms (Bishop et al., 2004), and ketanserin blocks
the locomotor sensitization observed in these animals (our un-
published data), without affecting the sustained activation of
ERK in MPC.
Studies have demonstrated that pharmacological stimulation
of NMDA receptors leads to activation of ERK in cortical neurons
(Bading and Greenberg, 1991; Xia et al., 1996; Arvanov et al.,
1997; Vanhoutte et al., 1999; Wang and O’Donnell, 2001). In this
investigation, both the competitive NMDA antagonist MK-801
and the noncompetitive antagonist CGS-19755 eliminated sus-
tained ERK phosphorylation in MPC, a finding suggestive of
NMDA dependence for the ERK phosphorylation. Thus, MPC of
neonate-lesioned rats sensitized with repeated doses of SKF-
38393 might undergo persistent biochemical adaptations similar
to other biological substrates of neuroplasticity such as long-term
potentiation (Impey et al., 1998) and memory processing (Ad-
ams and Sweatt, 2002). In addition, accumulated evidence dem-
onstrates an interaction of D1 and NMDA receptor functions
(Konradi et al.; 1996, Pei et al., 2004) (for review, see Adriani et
al., 1998; Salter, 2003) and dopamine modulation of glutamate
neurotransmission within the prefrontal cortex (Goldman-Rakic
and Selemon, 1997; Gonzalez-Islas et al., 2003; Otani et al., 2003;
Sesack et al., 2003). The present findings further illustrate the
presence of a dopamine– glutamate interaction in the MPC,
whereby repeated D1 agonist administration maintains
NMDA receptor-mediated responses in cells as reflected in
ERK phosphorylation.
The neuromolecular mechanisms underlying sustained ERK
hyperphosphorylation remain to be determined. Recent studies
have established a critical role for protein phosphatases in coor-
dinating neurotransmitter signaling (for review, see Greengard,
2001). Because phosphatases are presumed to rapidly deactivate
phosphorylated proteins in brain, the measured increase in cells
exhibiting phospho-ERK after SKF-38393 treatment could be re-
lated to altered phosphatase activity. Mitogen-activated protein
kinase phosphatases (MKPs) 1–3 can directly control nuclear
accumulation and persistent activation of ERK (for review, see
Pouyssegur et al., 2002). Interestingly, MKP1 and MKP3 expres-
sion in frontal cortex and other brain regions is differentially
altered by acute and chronic methamphetamine administration
to rats (Takaki et al., 2001). Thus, a reduction in MKP1–3 or a
related phosphatase might be a means by which ERK phosphor-
ylation could be sustained for an extended period. The answer to
this puzzle will have to be resolved in future experiments that
examine sustained ERK phosphorylation after SKF-38393-
mediated sensitization of neonate-lesioned animals.
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